A radium molecular entity with formula 223RaCl2. Used as as a radiotherapeutic agent for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. An alpha-emitter, radium-223 has a half-life of 11.4 days.
Stars
This entity has been manually annotated by the ChEBI Team.